SNS COLLEGE OF ALLIED HEALTH SCIENCE





DEPARTMENT OF CARDIOPULMONARY PERFUSION CARE TECHNOLOGY

COURSE NAME: PATHOLOGY

TOPIC: COMPLICATION AND MANAGEMENT ON CKD

UNIT: 1

FACULTY NAME: Ms. NIVETHA RAJA



PATIENT PRESENTATION - Mr.JK

DEFINITION {DEFINE STAGE } :

- Demographics: 68-year-old Male.
- Diagnosis: Severe Triple-Vessel CAD & Severe Aortic Stenosis (AS).
- Procedure: CABG x3 + Aortic Valve Replacement (AVR).
- 🔺 Major Comorbidities:
 - CKD Stage 3b (Baseline eGFR: 35 mL/min)
 - Type 2 Diabetes (HbA1c 8.5%)
 - Hypertension





RFT REPORT IDEATE

Test	Result	Reference	Clinical Significance
Creatinine	2.1 mg/dL	0.6-1.2	Confirming Stage 3b CKD
eGFR	35 mL/min	> 90	Reduced filtration; High AKI risk
Potassium (K+)	5.3 mEq/L	3.5-5.0	Mild Hyperkalemia (Arrhythmia risk)
Hemoglobin	10.5 g/dL	13.5-17.5	Anemia of Chronic Disease
BNP	550 pg/mL	< 100	Volume overload / Heart Failure

MEDICATION MANGEMENT STRATEGIES





Stop ACE Inhibitors

Lisinoprii held 24-48hrs prior to prevent refractory hypotension (vasoplegia) upon induction and bypass.



Hold Diuretics

Furosemide held morning of surgery to avoid hypovolemia, which exacerbates pre-renal injury.



Stop Metformin

Discontinued 48hrs prior to mitigate the risk of Lactic Acidosis should acute kidney injury develop.







PREOPERATIVE OPTIMISATION

INSTITUTIONS

CAUSES AND MANAGEMENT


- **Electrolyte Correction**: Treated K+ of 5.3 with Insulin/Glucose to target < 5.0 mEq/L before incision.
- Fluid Balance: Strict I/O monitoring to ensure euvolemia.
 Avoided dehydration (nephrotoxic) and overload (pulmonary edema).
- Blood Conservation: Hb 10.5 accepted. "Cell Saver" set up intra-operatively to wash and re-transfuse shed blood, minimizing donor exposure.
- Pacing Plan: External pads placed; high risk of conduction block post-AVR in CKD setting.







- High Flow Perfusion: Cardiac Index maintained > 2.4
 L/min/m² to ensure renal oxygen delivery.
- Perfusion Pressure (MAP): Target MAP > 70 mmHg (higher than standard 60). Vasopressors used liberally as renal autoregulation is impaired.
- Temperature: Mild hypothermia (34°C) only. Deep cooling avoided to reduce coagulopathy and rewarming shock.





INTRA OP RENAL MANAGEMENT

Hemodilution Management

Goal Hct > 24%: Severe hemodilution is poorly tolerated by ischemic kidneys.


Strategy: Minimized circuit priming volume.

Ultrafiltration (Hemoconcentrator) used throughout the run to remove excess crystalloid while preserving red cells.

Pharmacologic Support

Mannitol: 12.5g administered before CPB initiation to scavenge free radicals and promote osmotic diuresis.


Furosemide: Administered during rewarming to maintain Urine Output > 1 mL/kg/hr, preventing tubular stasis.







- The transition from OR to ICU is the highest risk period for Acute-on-Chronic Kidney Injury.
- Hemodynamics: Strict MAP > 75 mmHg. Norepinephrine titrated to maintain renal perfusion pressure.
- Fluid Balance: Aim for Negative Balance. Aggressive diuresis once stable to unload the heart.
- Nephrotoxins: NSAIDs strictly contraindicated. Renally adjusted doses for all antibiotics.







PROTOTYPE

♦ Uremic Bleeding


Problem: Platelet dysfunction common in CKD.

Management: If chest tube output > 200ml/hr, Desmopressin (DDAVP) administered to release Factor VIII/vWF. Platelets transfused if count < 100k.

∮ Hyperkalemia

Problem: Post-CPB cell lysis + renal insufficiency.

Management: Frequent K+ checks (q2h). Shift agents (Insulin/D50) used aggressively. Dialysis team on standby if K+ > 6.0 refractory to meds.



CASE OUTCOME



Successful Recovery

Mr. J.K. experienced a transient rise in Creatinine (peaking at 3.0 mg/dL) on Post-Op Day 2.

• Through aggressive fluid management and maintaining high perfusion pressures, Dialysis was avoided.

• Discharge: Day 7 to home. Creatinine trended down to 2.4 mg/dL.







Hemodyanonie. Stabwa enefillions to be trafform preprototymy Stabilication eun să liestelloguerme **Primary Indications** (Surgery Triggers) Huld Esaiance Aim for Zero or Negative net bance Саизітополец соцтопахе · Severe Triple-Vessel Monndnean Bradigetith Hame be mange-earolise Coronary Artarg Disease (CAD) Cannaticunio: Denagrati les le noperté sa covertes · Severe Aortic Stenosis (AS) Rempaication เอเรเมาใจกอกเล เดิบเลยนำเฉะ เติดักเลา Procadure: CABQ.16 + Aortic Valve Replacement: (AVR) **Key Comorbidities** Post-Operative Phase: ICU Management & amendin en amende and (Risk Drivers) Recovery (Hánaagement · Chronic Kidney Disease (CKD) Stage 8b Goal Provent Prodina Kidney For us.) (Beseline e SF64-86 M.: htt H) by Acuternat an igniplehie Perluston Parameters Kidney luju(ly;(Ax \$K) • Pourly Controlled Dlabetes (HbA1c: 8.5%) **High-Risk Cardiac** (High Targets) Megratatorud torarianson (CaM Hypertension Surgery (CKD Patient) Mean Arterial Pressure (MAPs Target > 70-75 mining USC Hacopressors liberally, Metabolic & Fluid Mr. J.K. 68M Management • CPB Flow Indes: Target > 2.41. (min/m2 · Electrolytes, Correct mlid Cardiac Planning Renal Protection & Monitoring Hyporkalema (K3 2.17 > Reserve Pacing Wires Insulin/OSD or Kayexalars Fluld Balance: Airn for Zero or Negative bance agaressive diureties (Furosemide) · Diabelleg: Start Insulin Drip to manage high glucose · Nephrotoxins: Strict Avoldance (NSAIDs, contrast, (HbA1c 8.0) adjected antibleteC) · Ancmia (Hb 10.5). Initiate Blood Conservation Protocol · Manitoring: Serial Cagofarine and Urine Output (q4A) → Check for KDIGO AKi criteria Temperature & Myocardial Protection Hypothermia, Mile Hypothermia (\$2.34thC) only **Complication Management** (Avaid deep cooling to Imli staS) Hyperkalemia (K³ – 6.0). High rrisk of DraVous littaion. · Caroloplegia, Use crystalloid (e.g. Custodiol) Treat with Insuln-(OSD IBicarb, or Kayexalute ro minimies volume load · Uremic Blooding. Use Desmopressin (DRAVP) IT · AFIb, Prophylactic Beta-B ockefts; treat Cosgulopathy is suspected idue to platelot dystunfwith Amiodarone (renaily · AFIb: Prophylactic Beta-Blockers, treat with Amiodar-

REFERNCES



- Kidney Injury Following Cardiac Surgery: A Review of Our Current Understanding, American Journal of Cardiovascular Drugs, 2025.
- Renal protection in cardiovascular surgery PMC review.
- Results of protocol-based perioperative management in CKD patients undergoing off-pump CABG (non-dialysis-dependent CKD).
- Prevention and Treatment of Cardiac Surgery Associated Acute Kidney
 Injury discussion of perfusion, dilution, CPB parameters.

